Title : Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models.

Pub. Date : 2019 Sep

PMID : 31160383






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kalpha Inhibitor TAK-117 in Preclinical Bladder Cancer Models. INK128 CREB regulated transcription coactivator 1 Mus musculus